Andrew J. Bentall, M.B., Ch.B., M.D.

Closed for Enrollment

• A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND) (ASCEND) Rochester, Minn. The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.
• BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation (BESTOW) Rochester, Minn.

  This is a randomized, multicenter, open-label, active control study to assess the safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. Approximately 120 de novo kidney transplant recipients will receive rATG (Thymoglobulin®) induction, corticosteroid maintenance, mycophenolate, and will be randomized 1:1 to receive either tegoprubart 20 mg/kg intravenously (IV) every 21 days after an initial loading period or twice daily oral tacrolimus.

• Development and Validation of a Kidney Transplant-Specific Supplement for the Patient Experience with Treatment and Self- Management (PETS) Survey Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate how treatment and self-care after kidney transplant impacts people’s lives, relationships, and finances.